Edward Acosta
Overview
Explore the profile of Edward Acosta including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
307
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li J, Melberg M, Kittilson A, Abdel-Mohsen M, Li Y, Aga E, et al.
JCI Insight
. 2024 Feb;
9(3).
PMID: 38329130
BACKGROUNDIdentifying factors that predict the timing of HIV rebound after treatment interruption will be crucial for designing and evaluating interventions for HIV remission.METHODSWe performed a broad evaluation of viral and...
2.
Piscitelli J, Nikanjam M, Best B, Acosta E, Mirochnick M, Clarke D, et al.
J Acquir Immune Defic Syndr
. 2021 Oct;
89(1):108-114.
PMID: 34629412
Background: A knowledge gap exists for dolutegravir (DTG) pharmacokinetics and safety during the first 4 weeks of life, preventing safe and effective DTG use in neonates. Setting: Population pharmacokinetic modeling...
3.
Li J, Aga E, Bosch R, Pilkinton M, Kroon E, MacLaren L, et al.
Clin Infect Dis
. 2021 Jun;
74(5):865-870.
PMID: 34117753
Background: Development of human immunodeficiency virus (HIV) remission strategies requires precise information on time to HIV rebound after treatment interruption, but there is uncertainty regarding whether modern antiretroviral therapy (ART)...
4.
Hassett K, Higgins J, Woods A, Levy B, Xia Y, Hsiao C, et al.
J Control Release
. 2021 May;
335:237-246.
PMID: 34019945
Lipid nanoparticles (LNP) are effective delivery vehicles for messenger RNA (mRNA) and have shown promise for vaccine applications. Yet there are no published reports detailing how LNP biophysical properties can...
5.
Bull M, Mitchell C, Soria J, Styrchak S, Williams C, Dragavon J, et al.
J Infect Dis
. 2020 Apr;
222(5):777-786.
PMID: 32274499
Background: During antiretroviral treatment (ART) with plasma HIV RNA below the limit of quantification, HIV RNA can be detected in genital or rectal secretions, termed discordant shedding (DS). We hypothesized...
6.
Acosta E, Bowlin T, Brooks J, Chiang L, Hussein I, Kimberlin D, et al.
J Infect Dis
. 2020 Mar;
221(Suppl 1):S32-S44.
PMID: 32134483
The development of therapeutics for cytomegalovirus (CMV) infections, while progressing, has not matched the pace of new treatments of human immunodeficiency virus (HIV) infections; nevertheless, recent developments in the treatment...
7.
Devanand D, Andrews H, Kreisl W, Razlighi Q, Gershon A, Stern Y, et al.
BMJ Open
. 2020 Feb;
10(2):e032112.
PMID: 32034019
Introduction: After infection, herpes simplex virus-1 (HSV1) becomes latent in the trigeminal ganglion and can enter the brain via retrograde axonal transport. Recurrent reactivation of HSV1 may lead to neurodegeneration...
8.
Taiwo B, Zheng L, Stefanescu A, Nyaku A, Bezins B, Wallis C, et al.
Clin Infect Dis
. 2017 Dec;
66(11):1689-1697.
PMID: 29253097
Background: Limited data exist on initial human immunodeficiency virus type 1 (HIV-1) treatment with dolutegravir plus lamivudine. Methods: A5353 is a phase 2, single-arm, pilot study of once-daily dolutegravir (50...
9.
King J, Acosta E
Curr Opin HIV AIDS
. 2009 Apr;
3(3):272-6.
PMID: 19372978
Purpose Of Review: Highly active antiretroviral therapy, which is widely available throughout developed countries, has become increasingly effective for treating the human immunodeficiency virus. In contrast, access to antiretroviral therapy...
10.
Khanlou H, Sayana S, Acosta E
J Int Assoc Physicians AIDS Care (Chic)
. 2009 Jan;
7(6):281-2.
PMID: 19164138
No abstract available.